First Time Loading...
M

Mayinglong Pharmaceutical Group Co Ltd
SSE:600993

Watchlist Manager
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
Watchlist
Price: 27 CNY -0.18% Market Closed
Updated: Apr 25, 2024
Section:
 

Relative Value

The Relative Value of one Mayinglong Pharmaceutical Group Co Ltd stock under the Base Case scenario is 21.36 CNY. Compared to the current market price of 27 CNY, Mayinglong Pharmaceutical Group Co Ltd is Overvalued by 21%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
21.36 CNY
Overvaluation 21%
Relative Value
Price
M
Worst Case
Base Case
Best Case

Valuation Multiples

3.6
P/S
P/S
Price to Sales
3.6
vs History
9
vs Industry
33
Median 3Y
2.9
Median 5Y
3
Industry
2.3
Forward
2.3
More Details
24.2
P/E
P/E
Price to Earnings
24.2
vs History
23
vs Industry
21
Median 3Y
21.2
Median 5Y
21.5
Industry
22.2
Forward
17.9
More Details
71.8
P/OCF
P/OCF
Price to OCF
71.8
vs History
7
vs Industry
5
Median 3Y
30.3
Median 5Y
23.8
Industry
16.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
1
Median 3Y
17.2
Median 5Y
17.2
Industry
22.6
More Details
3.2
P/B
P/B
Price to Book Value
3.2
vs History
20
vs Industry
24
Median 3Y
3
Median 5Y
3
Industry
2
More Details
2.9
EV/S
EV/S
Enterprise Value to Sales
2.9
vs History
11
vs Industry
38
Median 3Y
2.3
Median 5Y
2.4
Industry
2.5
Forward
1.9
More Details
6.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.5
vs History
20
vs Industry
33
Median 3Y
5.5
Median 5Y
5.6
Industry
5
More Details
20.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
20.5
vs History
12
vs Industry
18
Median 3Y
16.8
Median 5Y
16.8
Industry
13.2
Forward
11.1
More Details
20.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
20.5
vs History
12
vs Industry
22
Median 3Y
16.8
Median 5Y
16.8
Industry
16.5
More Details
57.8
EV/OCF
EV/OCF
Enterprise Value to OCF
57.8
vs History
7
vs Industry
6
Median 3Y
24.5
Median 5Y
18.1
Industry
15.5
More Details
669.6
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
669.6
vs History
0
vs Industry
1
Median 3Y
31.4
Median 5Y
18.3
Industry
17.2
More Details
4.7
EV/IC
EV/IC
Enterprise Value to IC
4.7
vs History
19
vs Industry
18
Median 3Y
4.3
Median 5Y
4.1
Industry
1.9
More Details

Multiples Across Competitors

Competitors Multiples
Mayinglong Pharmaceutical Group Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Mayinglong Pharmaceutical Group Co Ltd
SSE:600993
11.6B CNY 3.6 24.2 20.5 20.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
688.4B USD 20.2 131.4 59.4 68.2
DK
Novo Nordisk A/S
CSE:NOVO B
3.9T DKK 16.6 46.1 33.7 36.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
JP
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
82T JPY 255.8 9 733.7 1 771.8 4 320.3
US
Johnson & Johnson
NYSE:JNJ
352.6B USD 4.3 8.7 11.6 15.3
US
Merck & Co Inc
NYSE:MRK
329.1B USD 5.5 901.5 44.8 87.5
UK
AstraZeneca PLC
LSE:AZN
186.4B GBP 5.1 39 140.5 225.4
CH
Novartis AG
SIX:NOVN
184B CHF 4.3 13.6 9.9 16.4
CH
Roche Holding AG
SIX:ROG
174.7B CHF 3 15.2 8.4 9.9

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 131,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.